MEDI 4166

Drug Profile

MEDI 4166

Alternative Names: MEDI4166

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class Antihyperglycaemics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; PCSK9 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Type 2 diabetes mellitus

Most Recent Events

  • 11 Sep 2017 Adverse events data from a phase I trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 31 Jul 2017 Discontinued - Phase-II for Cardiovascular disorders in USA (MedImmune pipeline, July 2017)
  • 31 Jul 2017 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (SC) (MedImmune pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top